Sandip Kapadia serves as the Executive Vice President, Chief Financial Officer, and Chief Administrative Officer at Harmony Biosciences Holdings Inc., a pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases. Kapadia joined Harmony Biosciences in 2018 and has been instrumental in guiding the company through its growth and development, including its successful initial public offering (IPO) in 2020. Prior to his role at Harmony Biosciences, Kapadia held various leadership positions in the pharmaceutical and healthcare industries. He served as the Chief Financial Officer at Paragon Biosciences, LLC, where he played a key role in the company's strategic planning and financial management. Kapadia also spent over a decade at Takeda Pharmaceuticals, where he held several senior finance positions, including Vice President of Finance for the U.S. region. His extensive experience in financial strategy, corporate development, and operational management has been a valuable asset to Harmony Biosciences. In his current role at Harmony Biosciences, Kapadia is responsible for overseeing the company's financial operations, including accounting, financial planning and analysis, and investor relations. As Chief Administrative Officer, he also manages the company's human resources, legal, and compliance functions. Under his leadership, Harmony Biosciences has continued to expand its portfolio of innovative treatments and strengthen its position in the rare disease market. Kapadia's strategic vision and financial acumen have been crucial in driving the company's success and growth.